Gilead Sciences Inc. (All Sessions)
Gilead Sciences Inc. is an American research-based biopharmaceutical company that discovers, develops and commercialises medicines in areas of unmet medical need. The company focuses on developing medicines for the treatment of life-threatening illnesses such as HIV, AIDS, liver disease and serious cardiovascular and respiratory conditions.
Founded in 1987 by medical doctor Michael L. Riordan, Gilead Sciences Inc. has grown to become one of the world’s largest biopharmaceutical companies. The company is headquartered in Foster City, California in the United States and employs more than 9,000 people across six continents.
Gilead Sciences Inc. is listed on the NASDAQ Stock Market. The company is also a member of the NASDAQ Biotechnology Index (comprising securities of NASDAQ-listed companies classified as either Biotechnology or Pharmaceuticals) as well as the S&P 500 stock market index.
Gilead Sciences Inc. (All Sessions) Market Influences
Gilead Sciences Inc.’s share price is influenced by a range of different factors. Among these are governmental policy relating to the development and commercialisation of pharmaceuticals, economic policy and the general economic outlook, market sentiment and the industry’s performance and internal developments within the company (such as acquisitions and mergers, earnings reports, and staff appointment or layoffs).
Begin trading today! Create an account by completing our form
At One Financial Markets we are committed to safeguarding your privacy.
Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.
Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.
Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.
By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.